
Please try another search
BELLUS Health Inc (NASDAQ: BLU) shares are trading lower by 10.80% to $9.00 Thursday morning after the company priced an offering of 16,540,541 shares at a price of $9.25 per share.
BELLUS Health says the company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes.
Closing of the offering is expected to occur on July 18, 2022, subject to the satisfaction of customary closing conditions.
See Also: This Advertising Company Has A Better 5-Year Return Than Bitcoin, Ethereum, Starbucks (NASDAQ:SBUX), Ford, Microsoft (NASDAQ:MSFT), Apple (NASDAQ:AAPL), Disney And Amazon (NASDAQ:AMZN)
BELLUS Health is a clinical-stage biopharmaceutical development company.
According to data from Benzinga Pro, BELLUS Health has a 52-week high of $11.10 and a 52-week low of $2.60.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.